These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 31146885)

  • 1. Interferon Therapy Exacerbated Pulmonary Hypertension in a Patient with Hepatitis C Virus Infection: Pathogenic Interplay among Multiple Risk Factors.
    Tsuchiya H; Kioka H; Ozu K; Ohtani T; Yamaguchi O; Yazaki Y; Yamauchi-Takihara K; Sakata Y
    Intern Med; 2017; 56(9):1061-1065. PubMed ID: 28458313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy.
    Shan W; Hong D; Zhu J; Zhao Q
    Comput Math Methods Med; 2020; 2020():1391583. PubMed ID: 33029193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic cough associated with interferon/ribavirin therapy for hepatitis C.
    Dicpinigaitis PV; Weiner FR
    J Clin Pharm Ther; 2011 Jun; 36(3):416-8. PubMed ID: 21545621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
    Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM
    Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G; Tolvaj G; Halász T; Stotz G
    Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection.
    Sidhu-Malik NK; Kaplan AL
    J Drugs Dermatol; 2003 Oct; 2(5):570-3. PubMed ID: 14558408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon and ribavirin treatment for chronic hepatitis C deteriorates subclinical markers of vascular function.
    Georgiopoulos G; Alexopoulou A; Pouriki S; Vasilieva L; Laina A; Bampatsias D; Mani I; Kontogiannis C; Tousoulis D; Stamatelopoulos K; Dourakis SP
    Hellenic J Cardiol; 2019; 60(2):143-145. PubMed ID: 31146885
    [No Abstract]   [Full Text] [Related]  

  • 8. Current treatment for chronic hepatitis C.
    Davis GL
    Rev Gastroenterol Disord; 2001; 1(2):59-72. PubMed ID: 12120176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quality of life of patients with chronic hepatitis C: effect of treatments].
    Couzigou P
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B257-63. PubMed ID: 12180299
    [No Abstract]   [Full Text] [Related]  

  • 10. [The adherence in the treatment of chronic hepatitis C].
    Pawłowska M; Halota W
    Pol Merkur Lekarski; 2005 Apr; 18(106):469-72. PubMed ID: 16161937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus therapy to date.
    Foster G; Mathurin P
    Antivir Ther; 2008; 13 Suppl 1():3-8. PubMed ID: 18432157
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.